Aptimmune Biologics announces it has completed its Series B funding initiative, raising more than $6 million from several investors. This increases the combined total investment to almost $9 million, generated by the company through three rounds of funding.
“Aptimmune is thrilled to receive strong investor support during this critical time in our development,” said Aaron Gilbertie, Aptimmune CEO. “The Series B funds will provide the required resources to continue commercialization of BarricadeTM, our revolutionary inactivated mucosal vaccine formulation. In addition, the fresh cash infusion will allow us to expand our vaccine platform to other antigens important to veterinarians and swine producers around the globe.”
Participants in the company’s Series B funding include St. Louis Arch Angels, Arsenal Capital Management, Missouri Technology Corporation, Cultivation Capital, The Yield Lab, and various Midwest-based angel investors.
“St. Louis Arch Angels invested in Aptimmune starting in the fall 2016, and since that time we’ve observed the company’s steady progress, technically and commercially,” said Steve Wilhelm with Arch Angels. “We believe in Aptimmune’s mission and team and are pleased to extend our investment in Aptimmune as it changes vaccine paradigms and improves outcomes for customers.”
Arsenal Capital Management (ACM) was one of the first to invest in Aptimmune through its relationship with Common Place Holdings and has participated in all three funding rounds. “We are excited to be part of Aptimmune’s success story and have confidence in Aaron and his team’s ability to execute the 2018 business plan,” said Pete Reinecke, ACM managing director.
In addition, the company is relocating its headquarters and laboratory from Champaign, Ill., to the Bio-Research & Development Growth (BRDG) Park in St. Louis, Mo. Gilbertie says the move was due in large part to the exceptional financial and logistics support the company has received from investors and other businesses in the St. Louis area.
“We had outgrown our original facilities, and after thorough evaluation of several sites nationwide, we made the decision to relocate our headquarters and laboratory to BRDG Park in St. Louis,” Gilbertie explained.
The Missouri Technology Corporation (MTC), which supports innovation and entrepreneurship in the state, helped bring Aptimmune to Missouri by investing in their Series B financing through its Missouri IDEA Fund Program.
“Aptimmune represents the type of fast growing, next generation animal health company that Missouri is excited to support,” Bill Anderson, MTC executive director said. “Their decision to relocate to the 39 North innovation district is further proof of Missouri’s strength as a growing hub of ag tech innovation.”
The company’s new address is 1005 N. Warson Rd., St Louis, MO 63132. For more information on Aptimmune Biologics and its innovative swine vaccine products, visit Aptimmune.com.
Aptimmune Biologics, St. Louis, Mo., specializes in developing and marketing a portfolio of revolutionary inactivated mucosal vaccines that provide answers for the most costly diseases impacting the swine industry. Aptimmune’s first vaccines are focused on addressing two major viral respiratory pathogens, Porcine Reproductive and Respiratory Virus (PRRSV) and Influenza A virus in swine (IAV-S). To learn more visit www.aptimmune.com.